Results 131 to 140 of about 760 (154)
Some of the next articles are maybe not open access.

Sulbactam–Durlobactam for Carbapenem-Resistant Acinetobacter baumannii–calcoaceticus Complex Infections

American Journal of Therapeutics
Background: Antimicrobial resistance (AMR) is a major health crisis specifically associated with Acinetobacter. Among different Acinetobacter species, Acinetobacter baumannii is known as the greatest culprit concerning clinical significance. Of most importance, carbapenem-resistant A.
Nino Marzella   +4 more
openaire   +1 more source

Sulbactam-Durlobactam, A Novel Drug for the Treatment of Multidrug Resistant Acinetobacter baumannii Infections - A Systematic Review

Infectious Disorders - Drug Targets
Background: Sulbactam-durlobactam (SUL-DUR) has been tested in vitro for its ability to gen- erate resistance in clinical isolates of Acinetobacter species. According to prior studies, combining durlobac- tam with sulbactam causes sulbactam-resistant isolates to become more active and revert to susceptibility.
Hemasri Velmurugan   +4 more
openaire   +2 more sources

Sulbactam–durlobactam for infections caused by Acinetobacter baumannii–calcoaceticus complex – Authors' reply

The Lancet Infectious Diseases, 2023
Keith S, Kaye   +3 more
openaire   +2 more sources

Durlobactam, a Diazabicyclooctane β-Lactamase Inhibitor, Inhibits BlaC and Peptidoglycan Transpeptidases of Mycobacterium tuberculosis

ACS Infectious Diseases
Peptidoglycan synthesis is an underutilized drug target in Mycobacterium tuberculosis (Mtb). Diazabicyclooctanes (DBOs) are a class of broad-spectrum β-lactamase inhibitors that also inhibit certain peptidoglycan transpeptidases that are important in mycobacterial cell wall synthesis.
Mary Nantongo   +12 more
openaire   +2 more sources

Unraveling sulbactam-durlobactam: insights into its role in combating infections caused by Acinetobacter baumannii

Expert Review of Anti-infective Therapy
Carbapenem-resistant Acinetobacter baumannii (CRAB) is a critical priority pathogen posing a substantial threat to our public health due to its virulence and resistance to broad-spectrum antimicrobials. Sulbactam-durlobactam (Xacduro) is a newly approved β-lactam-β-lactamase inhibitor combination agent with potent in vitro and in vivo activity against ...
Yakun, Fu   +2 more
openaire   +2 more sources

Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity AgainstAcinetobacterSpecies

Clinical Infectious Diseases, 2023
Alita Miller   +2 more
exaly  

Home - About - Disclaimer - Privacy